Data lacking for perampanel

摘要

ASSESSING the place of perampanel in the treatment of epilepsy is hampered by a lack of comparative controlled trials and published health economic analyses, according to the latest Drug and Therapeutics Bulletin. However, the DTB concludes that, on current evidence, "perampanel is an extra drug to add to the list of adjunctive treatments to be considered by a tertiary epilepsy specialist".